Novo Nordisk expects Ozempic, which has been on the market since 2017, will be on Medicare's list of drugs to negotiate ...

Drugmakers have started 2025, implementing price hikes for 583 products within the first two days of the new year alone, ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

After years of delays and debate, 2024 was the year when several health initiatives started to move forward. And advocates ...

Empagliflozin is also indicated to reduce the ... portfolio and reaffirms our commitment to delivering innovative and cost-effective medications for patients across India,” said Nilesh Gupta ...

More than 110,000 North Carolinians are projected to benefit from a $2,000 annual cap on out-of-pocket costs for covered prescription drugs for Medicare Part D participants.

Medicare, in collaboration with Medicaid, has negotiated with pharmaceutical companies to reduce the prices of ten high-cost, ...

SGLT-2 inhibitors include empagliflozin (Jardiance) and dapagliflozin (Farxiga), and GLP-1 agonists include semaglutide (Ozempic) and liraglutide (Victoza). "The use of these evidence-based ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

INR:7796. best site for esports betting Confirmed! State Council News: Consumables prices will be significantly adjusted Kelun Pharmaceutical's "Emp ...

With list prices of $8.94 per day for the monotherapy and metformin combinations, the companies are hoping to gain ground on Farxiga and Jardiance by undercutting them – Farxiga costs $11.57 per ...

German family-owned pain focused drugmaker Grünenthal announced today that Prof Dr Uli Brödl will assume the role of chief ...